Search Within

Esther Naomi Drill

Formats
  1. Journal Article (52)
  2. Meeting Abstract (43)
  3. Research Letter (2)
Groups
  1. Epidemiology and Biostatistics (97)
  2. Principal Biostatisticians (97)
  3. Department of Medicine (82)
  4. Center for Hematologic Malignancies (55)
  5. Hematologic Malignancies, Division of (54)
  6. Survivorship Research (49)

More Groups

People
  1. Alison Moskowitz (29)
  2. Andrew Zelenetz (28)
  3. Anita Kumar (28)
  4. Steven Horwitz (27)
  5. Ariela Noy (26)
  6. Paul Hamlin (24)

More People

Years
  1. 2025 (4)
  2. 2024 (17)
  3. 2023 (10)
  4. 2022 (10)
  5. 2021 (12)
  6. 2020 (5)

More Years

Publications
  1. Blood (21)
  2. Journal of Clinical Oncology (12)
  3. Haematologica (6)
  4. Clinical Cancer Research (4)
  5. Hematological Oncology (4)
  6. American Journal of Surgical Pathology (3)

More Publications

Publishers
  1. American Society of Hematology (23)
  2. American Society of Clinical Oncology (13)
  3. Elsevier Inc. (9)
  4. American Association for Cancer Research (7)
  5. Ferrata Storti Foundation (6)
  6. Lippincott Williams & Wilkins (5)

More Publishers

Results (97)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A non-canonical tricarboxylic acid cycle underlies cellular identity
    Journal Article

    Arnold, P. K.; Jackson, B. T.; Paras, K. I.; Brunner, J. S.; Hart, M. L.; Newsom, O. J.; Alibeckoff, S. P.; Endress, J.; Drill, E.; Sullivan, L. B.; more...
    Nature (2022)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Real-world assessment of patient care and practice efficiency with the introduction of subcutaneous rituximab
    Journal Article

    Drill, E.; Qiu, A.; Shapouri, S.; Tu My, T.; Ravelo, A.; Schade, J.; Dawson, K.; Matasar, M.
    Oncology (Norwalk) (2021)

    Fulltext@MSK | Save
  • IVAC with or without rituximab for relapsed or refractory B-cell non-Hodgkin lymphomas: Real-world experience in the modern era
    Journal Article

    Buege, M. J.; Dao, P. H.; Drill, E.; LeVoir, A.; Pak, T.; Peterson, T. J.; Straus, D. J.
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC)
    Meeting Abstract

    Grisham, R. N.; Vergote, I.; Banerjee, S. N.; Drill, E. N.; Fabbro, M.; Mirza, M. R.; Romero, I.; Coleman, R. L.; Oza, A. M.; Hilpert, F.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Genetic determinants of outcome in intrahepatic cholangiocarcinoma
    Journal Article

    Boerner, T.; Drill, E.; Pak, L. M.; Nguyen, B.; Sigel, C. S.; Doussot, A.; Shin, P.; Goldman, D. A.; Gonen, M.; Allen, P. J.; more...
    Hepatology (2021)

    Fulltext@MSK | Save
  • Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma
    Journal Article

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Constine, L. S.; Dandapani, S. V.; Drill, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Cardiotoxicity risk in patients with non‐Hodgkin lymphoma receiving epoch after prior anthracycline exposure
    Meeting Abstract

    Buege, M. J.; Dao, P. H.; Drill, E.; Horwitz, S. M.; LeVoir, A.; Pak, T.; Peterson, T. J.; Matasar, M. J.
    Hematological Oncology (2021)

    Fulltext@MSK | Save